Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Specialized Diet and Husbandry for Metabolic Disease Models (db/db mice) in the UK

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Specialized Diet and Husbandry for Metabolic Disease Models (db/db mice) in the UK

Specialized Husbandry for Metabolic Disease Models for UK Sponsors

CELL & GENE | RNA | BIOLOGICS

** Precision Husbandry for Predictive Metabolic Data.

Effective preclinical evaluation of therapeutics for metabolic diseases requires in vivo models that are precisely managed to minimize experimental variability. For genetically modified models, such as the db/db mouse, subtle deviations in diet, housing, and handling can significantly alter phenotypes and confound study outcomes. Franklin Biolabs provides highly controlled, specialized husbandry and dietary protocols from our US-based facilities, ensuring the generation of consistent, high-integrity data for UK sponsors advancing complex cell and gene therapies. Our approach mitigates common variables, supporting a more direct path toward an 18-24 month IND/CTA timeline.

What specific dietary controls are implemented for db/db models?
We utilize purified, fixed-formula diets with defined macronutrient and micronutrient profiles. This eliminates the lot-to-lot variability inherent in standard chow, which can impact glycemic control and lipid metabolism, ensuring a stable metabolic baseline throughout the study.
How does environmental enrichment impact metabolic study outcomes?
Appropriate environmental enrichment is managed to reduce chronic stress, which can elevate corticosterone levels and introduce a significant confounding variable in glucose metabolism and insulin sensitivity assessments. Our protocols are designed to promote species-typical behaviours while maintaining study consistency.
What is the standard health monitoring frequency for these sensitive models?
All cohorts undergo daily welfare checks by trained technical staff. For metabolic disease models, this is supplemented by at least weekly monitoring of body weight and blood glucose levels, with frequency adjusted based on specific study protocols and model progression.
How do you ensure study conduct aligns with international regulatory expectations, including the MHRA?
Through our strategic partners, including the Bioculture Group, all studies are conducted in AAALAC-accredited facilities in full compliance with the US Animal Welfare Act. Our GxP-compliant data packages are designed to support regulatory submissions to global bodies, including the FDA and the UK’s MHRA, ensuring data integrity and a clear path to clinical trial authorisation.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Mitigating Phenotypic Drift with Protocolized Husbandry

The translational value of data derived from metabolic disease models is directly dependent on the stability of the model’s phenotype. Factors such as diet composition, caloric access, light cycles, and housing density can significantly influence key endpoints like insulin resistance, body weight, and glucose tolerance. Uncontrolled variables introduce noise that can mask the true therapeutic effect of a novel biologic or gene therapy.

Franklin Biolabs implements rigorous, protocol-driven husbandry programs designed to normalize these environmental factors. Our approach includes:

  • Controlled Nutrition: Standardized, purified diets are used to ensure consistent caloric and macronutrient intake across all study arms and over time.

  • Automated Environmental Systems: Our >100,000 sq ft facility is equipped with systems that maintain precise control over temperature, humidity, and photoperiods, which are important for regulating circadian rhythms tied to metabolism.

  • Social Housing Strategy: We develop social housing plans that balance the need for animal welfare with the specific requirements of the study, such as the need for individual metabolic cages for data collection.

Supporting Advanced Therapeutic Modalities

The requirement for a stable in vivo environment is amplified when evaluating advanced therapies. For instance, research demonstrating the correction of a metabolic liver disease using a dual AAV system with CRISPR-Cas9 (PMID: 26829317) highlights the profound therapeutic potential of gene editing. The study’s observation that efficacy was highest in the neonatal period points to the absolute necessity of specialized husbandry capable of supporting sensitive newborn subjects through complex procedures. Reproducing and building upon such findings requires an in vivo operations platform that can deliver this level of specialized care consistently.

Our approach to process optimization and manufacturing efficiency helps reduce preclinical development timelines and costs for sponsors. By standardizing husbandry protocols and environmental controls, we increase the reproducibility and reliability of in vivo studies, ultimately accelerating program development.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

Animal Welfare and Global Regulatory Adherence

All programs are designed to meet and exceed globally recognized standards of care. Our animal care philosophy is guided by the principles of the 3Rs (Replacement, Reduction, and Refinement). This framework, supported by conducting studies in AAALAC-accredited facilities and adhering to USDA regulations, ensures not only ethical conduct but also enhances the scientific validity of our studies. By refining housing and procedures to minimize stress, we improve animal well-being and reduce physiological variability that can compromise data quality for our international sponsors.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities